Wall Street Zen Upgrades Acurx Pharmaceuticals (NASDAQ:ACXP) to Sell

Acurx Pharmaceuticals (NASDAQ:ACXP) was upgraded by research analysts at Wall Street Zen to a “sell” rating in a report released on Saturday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a research report on Monday. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Acurx Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $31.00.

Acurx Pharmaceuticals Trading Down 1.5%

NASDAQ:ACXP opened at $1.98 on Friday. Acurx Pharmaceuticals has a twelve month low of $1.33 and a twelve month high of $21.00. The company has a 50-day moving average of $3.01 and a 200-day moving average of $3.66. The firm has a market cap of $5.66 million, a price-to-earnings ratio of -0.35 and a beta of -1.92.

Acurx Pharmaceuticals (NASDAQ:ACXP) last posted its quarterly earnings data on Thursday, March 12th. The company reported ($0.31) earnings per share for the quarter, beating the consensus estimate of ($1.01) by $0.70. On average, research analysts forecast that Acurx Pharmaceuticals will post -2.68 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in ACXP. Armistice Capital LLC acquired a new position in shares of Acurx Pharmaceuticals in the second quarter worth about $551,000. Geode Capital Management LLC acquired a new position in shares of Acurx Pharmaceuticals in the fourth quarter worth about $31,000. Jane Street Group LLC acquired a new position in shares of Acurx Pharmaceuticals in the fourth quarter worth about $27,000. Finally, Millennium Management LLC acquired a new stake in shares of Acurx Pharmaceuticals during the fourth quarter worth approximately $103,000. 11.53% of the stock is currently owned by institutional investors and hedge funds.

About Acurx Pharmaceuticals

Acurx Pharmaceuticals, Inc, headquartered in King of Prussia, Pennsylvania, is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel anti‐infective therapies. The company’s research platform leverages insights into bacterial virulence regulation and quorum sensing pathways to design small-molecule candidates aimed at reducing pathogen toxicity and biofilm formation. By targeting key mechanisms of infection rather than bacterial viability alone, Acurx seeks to offer differentiated treatment options that may help address the growing challenge of antibiotic resistance.

Acurx’s lead product candidates are being developed to treat acute bacterial skin and skin structure infections (ABSSSI), including cases caused by drug-resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA).